A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Clinical trial NCT05488314 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05488314
- Sponsor
- Janssen Research & Development, LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-13
- Primary completion
- 2027-04-28
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.